The Food and Drug Administration (FDA) has granted regulatory approval for Zaynich™ (cefepime-zidebactam), marking a foundational milestone in global antimicrobial development.
Developed by the Indian pharmaceutical firm Wockhardt, this novel combination therapy functions as a multi-target beta-lactam/beta-lactamase inhibitor (BL-BLI) designed specifically to combat highly resistant Gram-negative pathogens.
Indicated for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis in adult populations, Zaynich addresses a critical gap in treating infections driven by metallo-beta-lactamase (MBL) and extreme-drug-resistant (XDR) strains.
In its global Phase 3 non-inferiority trials, the drug demonstrated an 89.1% clinical cure rate, successfully establishing therapeutic equivalence to established treatment regimens while overcoming traditional mechanism-specific resistance pathways.
Beyond its immediate clinical utility in mitigating the global burden of antimicrobial resistance (AMR), this approval represents a significant geopolitical shift in pharmaceutical innovation, establishing India's capacity to transition from a generic manufacturing ecosystem into a primary hub for New Chemical Entity (NCE) discovery.
Read more via the link